Exparel vs. Bupivacaine for Postoperative Pain After Hernia Surgery
Trial Summary
What is the purpose of this trial?
While studies have shown improved postoperative pain control with TAP blocks after inguinal and ventral hernia repair, data comparing Liposomal bupivacaine (Exparel) to bupivacaine alone in formulation of the TAP block is particularly scarce. Therefore, we designed a prospective, randomized trial comparing the postoperative pain control in minimally invasive ventral and inguinal hernia repair patients who receive an Exaparel-based TAP block compared to the traditional bupivacaine (Marcaine) TAP block.
Research Team
Leslie Son, PhD
Principal Investigator
Our Lady of the Lake Hospital
Eligibility Criteria
This trial is for adults over 18 with ventral or inguinal hernias needing surgery. It's not for those under 18, chronic pain patients, individuals with very large (>10 cm) or small (<4 cm) defects, allergies to bupivacaine, recurrent hernia history, emergency surgeries, other concurrent surgeries, heavy alcohol users, if the procedure turns open surgery, people weighing less than 50kg or with a BMI over 45.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo minimally invasive ventral or inguinal hernia repair with a TAP block using either Exparel or Marcaine
Post-operative Monitoring
Participants complete VAS pain assessments and record narcotic use at home, with daily follow-up calls from the study team
Follow-up
Participants return for a follow-up visit to provide VAS assessments and unused narcotics
Treatment Details
Interventions
- Bupivacaine
- Liposomal Bupivacaine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Leslie Son
Lead Sponsor
Our Lady of the Lake Hospital
Collaborator
Our Lady of the Lake Regional Medical Center
Collaborator